AYTU - Aytu BioScience, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7695
-0.0231 (-2.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.7926
Open0.7500
Bid0.0000 x 1000
Ask0.0000 x 2200
Day's Range0.7200 - 0.7951
52 Week Range0.6800 - 2.6100
Volume165,360
Avg. Volume119,741
Market Cap16.118M
Beta (3Y Monthly)3.68
PE Ratio (TTM)N/A
EPS (TTM)-1.5910
Earnings DateFeb 5, 2020 - Feb 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
  • ACCESSWIRE

    Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary

    ENGLEWOOD, CO / ACCESSWIRE / November 19, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Tuzistra® XR, the only FDA-approved 12-hour codeine-based cold-cough syrup, is now covered by a leading national pharmacy benefit manager (PBM). This PBM contract provides more than six million covered lives with unrestricted patient access to Tuzistra XR across the PBM's national formularies and client plans servicing government clients.

  • Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates

    Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE

    Aytu Reports First Quarter 2020 Financial Results

    ENGLEWOOD, CO / ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical ...

  • ACCESSWIRE

    Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

    ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's Executive Vice President of Commercial Operations. Mr. Phillips' hiring became effective November 8, 2019 following the recently announced acquisition of a portfolio of six prescription products from Cerecor, Inc. (the "Commercial Portfolio") and the accompanying commercial team supporting the products' growth.

  • ACCESSWIRE

    Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update

    ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter ended September 30, 2019 on November 14, 2019, at 4:30 p.m. ET. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

  • GlobeNewswire

    Kaskela Law LLC Announces Stockholder Investigation of Aytu BioScience, Inc. – AYTU

    PHILADELPHIA, Nov. 04, 2019 -- Kaskela Law LLC is investigating Aytu BioScience, Inc. (“Aytu”) (NASDAQ: AYTU) on behalf of the company’s stockholders.  The investigation seeks.

  • ACCESSWIRE

    Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase

    ENGLEWOOD, CO / ACCESSWIRE / November 4, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of the previously announced purchase of a $12.4M annual revenue prescription product portfolio (the "Commercial Portfolio") and accompanying commercial infrastructure from Cerecor. With this acquisition, along with the previously announced acquisition of Innovus Pharmaceuticals, combined company annual revenue increases to over $44 million, based on combined company revenue for the twelve months ending June 30, 2019.

  • Form D Friday: Greenwood Village-based securities firm raising $50M for real estate fund
    American City Business Journals

    Form D Friday: Greenwood Village-based securities firm raising $50M for real estate fund

    Form D Friday is a Denver Business Journal feature highlighting regulatory filings from Denver-area companies raising capital for new projects, creating new venture funds or expanding their businesses. Parsonex Opportunity Fund I of Englewood is raising $50 million in common units of LLC membership interests for a business in the real estate industry, according to a Form D filed on Oct. 29. There is one investor so far.

  • ACCESSWIRE

    Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary

    Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions ...

  • ACCESSWIRE

    Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study

    Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone ...

  • ACCESSWIRE

    Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17

    Investigator-initiated, Phase IV study results will be presented today at 75 th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session ENGLEWOOD, ...

  • ACCESSWIRE

    Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio

    ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of an asset purchase agreement to acquire a portfolio of prescription products from Cerecor, Inc. (the "Commercial Portfolio"). The Commercial Portfolio and accompanying commercial infrastructure generated $12.4 million in net revenue and was profitable on a standalone basis for the twelve months ending June 30, 2019.

  • ACCESSWIRE

    Aytu BioScience Announces $10 Million Private Placement

    ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is pleased to announce that it has entered into definitive agreements with two institutional investors for the purchase and sale in a private placement of $10 Million of Series F Convertible Preferred Stock and warrants to purchase common stock. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing.

  • ACCESSWIRE

    Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market

    Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions ...

  • ACCESSWIRE

    Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019

    Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO / ACCESSWIRE ...

  • ACCESSWIRE

    Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives

    During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue ENGLEWOOD, CO / ACCESSWIRE / September ...

  • ACCESSWIRE

    Aytu BioScience to Report Fiscal FY 2019 Results and Business Update

    ENGLEWOOD, CO / ACCESSWIRE / September 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, ...

  • ACCESSWIRE

    Aytu BioScience to Present at Ladenburg Thalmann 2019 Healthcare Conference

    ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and David Green, Chief Financial Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference at 10:00 a.m. ET on Tuesday, September 24, 2019 at the Sofitel NYC. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, an FDA-approved, commercial-stage prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

  • ACCESSWIRE

    Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

    ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / September 12, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing. This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock.

  • ACCESSWIRE

    Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa

    ENGLEWOOD, CO / ACCESSWIRE / September 10, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that MiOXSYS®, the company’s first-in-class seminal oxidative stress test for the assessment of male infertility, is now available in South Africa and is offered through Androcryos, the largest sperm bank on the African continent. MiOXSYS, the Male Infertility Oxidative System, is CE marked and cleared by Health Canada, Australia's TGA, and Mexico's COFEPRIS.

  • Do Insiders Own Lots Of Shares In Aytu BioScience, Inc. (NASDAQ:AYTU)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Aytu BioScience, Inc. (NASDAQ:AYTU)?

    A look at the shareholders of Aytu BioScience, Inc. (NASDAQ:AYTU) can tell us which group is most powerful. Insiders...

  • ACCESSWIRE

    Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals

    Co-promotion nearly doubles Tuzistra XR sales force Poly’s geographic footprint covers approximately 750,000 antitussive prescriptions annually accounting for approximately $128 million in annual revenue ...

  • What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
    Zacks

    What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?

    On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.

  • ACCESSWIRE

    Aytu BioScience Announces First ZolpiMist(TM) Clinical Study Results Demonstrating More Rapid Sleep Onset with Lingual Spray Zolpidem versus Oral Tablet

    ENGLEWOOD, CO / ACCESSWIRE / August 5, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the publication of a clinical study in the journal Pharmacy and Pharmacology, demonstrating that ZolpiMist, Aytu BioScience’s lingual spray formulation of zolpidem, achieves sleep onset more quickly than the oral tablet form of zolpidem (brand name Ambien®) in patients seeking short-term treatment for insomnia. This new scientific report describes a post-hoc analysis of data from the pivotal Phase 3 study of ZolpiMist.